C-ILI6EXO Biologics
exosomes, extracellular vesicles, MSC-derived EVs
deliverydeliveringextracellular vesicle
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ILI6
C-ILI6C-ILI6exosomes, extracellular vesicles, MSC-derived EVs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in extremely premature neonates. The study population includes babies born between 23 and 28 (27 + 6 days) weeks of gestational age and body weight between 500g and 1,500 g. Thirty-six subjects will receive one or three administrations of the three doses of EXOB-001 via the endotracheal route in phase 1. In phase 2, two dosages based on the results of phase 1 will be selected and a total of 203 subjects will be randomised to receive either EXOB-001 or placebo (saline solution). Infants will be followed up to 2 years of corrected age (end of study).
Pour Hugues Wallemacq , CEO Exo Biologics , Liège a une place à prendre dans le développement de la thérapie cellulaire. On tente de comprendre pourquoi avec Catherine Robert, GRE-Liège Qu’est-ce que la thérapie cellulaire ? « En résumé, c’est utiliser nos cellules et les modifier. Puis nous les réinjecter pour nous traiter. Exo Biologics explore de nouvelles voies thérapeutiques dont par exemple, traiter l’inflammation pulmonaire chez les prématurés. » Pourquoi s’installer à Liège ? « Une des raisons principales, c’est l’existence d’un réseau scientifique médical important, mais aussi d’un soutien financier important des organes publics comme la Région Wallonne, Noshaq, SFPI. Les critères pour lesquels on vient à Liège, ce sont le bras financier et le bras médical. » Exo Biologics, aujourd'hui située près d'Anvers, vient poursuivre le développement clinique de ses thérapies en bord de Meuse. La petite #biotech installera dans les nouveaux bâtiments du #LégiaPark dès septembre 2
CDMO launched to service increasing demand for exosomes - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business Regulatory Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science Ab
EXO Biologics secures €16M to develop Novel Exosome Therapies - FoundersToday Skip to content Home About Us Startup Magazine Case Studies PR Coverage Home About Us Startup Magazine Case Studies PR Coverage Linkedin Instagram Facebook Youtube Search Linkedin Instagram Facebook Youtube Funding News Founder Stories Leadership Learning Digital Magazine Podcast Submit Press Release Funding News Founder Stories Leadership Learning Digital Magazine Podcast Submit Press Release Search Funding News Founder Stories Leadership Learning Digital Magazine Podcast Submit Press Release Funding News Founder St … lease Funding News Founder Stories Leadership Learning Digital Magazine Podcast Submit Press Release Search EXO Biologics secures €16M to develop Novel Exosome Therapies April 26, 2024 Share now Read this article in: © EXO Biologics EXO Biologics, a clinical-stage biotech company based in Liège, Belgium, has secured €16 million in Series A funding to advance its pioneering work with exosomes for therapeutic use. The funding includes €9 million from investors such as Noshaq, F
Two industry-first milestones for the exosome field - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business Regulatory Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science About
Expanding Exosome-Based Therapies genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine Get GEN eNewsletters Search Facebook Linkedin RSS Twitter
EXO Biologics' Industry Firsts- GMP Cert For EU Exosome Manufacturing Facility And Large Molecule Loading Into Exosomes Get more pharma outsourcing insight with our FREE newsletter sign me up Log In or Subscribe Explore CDMO Outsourcing Outsourcing 101 Preparing to Outsource Selecting a CDMO Onboarding & Tech Transfer Managing CDMOs Find Suppliers Bioanalytical Services Biologic Drug Substance Biologic Drug Product Cell & Gene Clinical Supply Fill/Finish Small Molecule API Small Molecule Drug Product Watch Now STREAM Video Channel Outsourced Pharma Capabilities Update Outsourced Pharma … ation of this new unit operation to provide a seamless platform toward clinical application. The loading step is to be incorporated in ExoXpert’s cutting edge ExoPulse(TM) exosome manufacturing GMP platform. ExoPulse is currently being used by several partners to develop exosome-based products with a derisked path to clinical. Exosomes, as naturally occurring extracellular vesicles, are increasingly recognized for their ability to transport biologically active cargo, su
EXO Biologics | BIO-Europe Spring You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. March 23–25, 2026 FIL (Feira Internacional de Lisboa), Lisbon, Portugal March 31 – April 1, 2026 | Digital Partnering Home home What to expect expand_more Who attends? Reception
EXO Biologics completes dosing of first cohort in first EMA-approved MSC-based exosome clinical trial About Us Our Technology Our Pipeline News Careers Contact Us Toggle navigation News EXO Biologics completes dosing of first cohort in first EMA-approved MSC-based exosome clinical trial Liège, Belgium, June 24, 2024 – EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, today announces it has completed dosing of the first cohort of patients in EVENEW. Study to target Bronchopulmonary Dysplasia, the most common cause of fatality in pre-natal birth.
ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes About Us Our Technology Our Pipeline News Careers Contact Us Toggle navigation News ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes Liege, Belgium, January 31, 2024 – EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, today announces the worldwide launch of ExoXpertTM, a contract development and manufacturing organization ... Liege, Belgium, January 3
EXO Biologics Received FDA Rare Pediatric Disease Designation for EXOB-001 for Prevention of BPD in Preterm newborns. About Us Our Technology Our Pipeline News Careers Contact Us Toggle navigation News EXO Biologics Received FDA Rare Pediatric Disease Designation for EXOB-001 for Prevention of BPD in Preterm newborns. Liège, Belgium 30 September 2022 –Exo Biologics announced that the US Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) to its lead product candidate EXOB-001. Liège, Belgium 30 September 2022 – Exo Biologics announced that the
EXO Biologics Pioneers with EVENEW Clinical Trial in Broncho Pulmonary Dysplasia. About Us Our Technology Our Pipeline News Careers Contact Us Toggle navigation News EXO Biologics Pioneers with EVENEW Clinical Trial in Broncho Pulmonary Dysplasia. First MSC-derived Extracellular Vesicles interventional study approved by the European Medicines Agency. Liège, Belgium 17 July 2023 – EXO Biologics SA , a Belgian biotech company committed to developing biopharmaceuticals using Extracellular Vesicles (EVs) to treat rare diseases with high unmet medical needs, received approval from the
EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply. About Us Our Technology Our Pipeline News Careers Contact Us Toggle navigation News EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply. The funding will primarily strengthen EXO Biologics’ subsidiary ExoXpert®, the exosome specialist CDMO, support the first EMA approved MSC-derived exosome clinical trial, and fund the ongoing development of the ExoPulseTM platform to produce unmodified and RNA or drug-loaded … sp; About Noshaq Noshaq, headquartered in Liège, is an investment fund offering financial support for SMEs' growth and development in the Liège Region. Over the years, Noshaq has developed a range of financing vehicles that align with the market's needs, trends, and strategy. Each service offered by Noshaq (capital - loan - leasing) is always determined according to the demands and needs of the owner-investor. The objective is always to have a leverage ef
EXO Biologics CEO, Founder, Key Executive Team, Board of Directors & Employees Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partners
EXO Biologics (0732.982.379) : Chiffre d'affaires & dirigeants Copié Copié Copié Copié Copié Copié Copié Copié Copié Copié Copié Copié Copié Copié Pappers Pro La version avancée de Pappers pour les usages professionnels · Données exclusives : scoring de solvabilité, risque de défaillance, alertes sur vos entreprises suivies · Fonctionnalités avancées : filtres de recherche poussés, exports en masse, accès multi-utilisateurs · Couverture internationale : la Belgique et 9 autres pays européens dans la même interface En savoir plus Dernière mise à jour : le 14/06/2026 EXO Biologics Activ
ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes - Exosome RNA --> Don't Miss Aptamer-Based Extracellular Vesicle Protein Profiling for Prognostic Assessment in Triple-Negative Breast Cancer Novel nanowire device offers rapid, noninvasive cancer detection Engineering extracellular vesicles for neurological repair ANZSEV 2026 Scientific Meeting Standardization efforts aim to improve extracellular vesicle RNA biomarker research New European Research Project RESOLVE Aims to Develop Innovative Therapy for Chronic Neuropathic Pain A study led by IGTP id
EXO Biologics Secures Up To EUR 16 Million In Series A Funding For Exosome Therapeutic Development And Clinical Supply. Get more pharma outsourcing insight with our FREE newsletter sign me up Log In or Subscribe Explore CDMO Outsourcing Outsourcing 101 Preparing to Outsource Selecting a CDMO Onboarding & Tech Transfer Managing CDMOs Find Suppliers Bioanalytical Services Biologic Drug Substance Biologic Drug Product Cell & Gene Clinical Supply Fill/Finish Small Molecule API Small Molecule Drug Product Watch Now STREAM Video Channel Outsourced Pharma Capabilities Update Outsourced Pharma … st CDMO, support the first EMA approved MSC-derived exosome clinical trial, and fund the ongoing development of the ExoPulse platform to produce unmodified and RNA or drug-loaded exosomes. EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, today announces the successful securing of a total of up to EUR 16 million in Series A funding. EXO Biologics will use the funds to support its ongoing and future clinical trials. It will also use f
ExoXpert, by Exo Biologics, the CDMO specialized in exosomes About Us About Us Our History Leadership Team Why exosomes Services ExoPulse™ platform Buy Exosomes Process Development GMP manufacturing Facility | News Careers Contact About us Making exosomes an industrial reality Who we are History Leadership team Who we are ExoXpert is a subsidiary of EXO Biologics , a leading biotech which develops affordable and accessible exosome therapy for patients with unmet medical needs ExoXpert is an exosome specialized CDMO providing development and manufacturing capabilities to exosome product develop … am? Applying for a job at ExoXpert and become a shaper of the exosome expansion Apply now Boulevard de Patience et Beaujonc 3/2 4000 Liège – Belgium +32 468-009-199 [email protected] Created by Legal Cookies Privacy Manage Cookie Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consen
EXO Biologics & ExoXpert achieve two critical industry-first milestones for the exosome field About Us Our Technology Our Pipeline News Careers Contact Us Toggle navigation News EXO Biologics & ExoXpert achieve two critical industry-first milestones for the exosome field • First GMP certification of European exosome-specialist manufacturing facility • Successful loading of mRNA and DNA payloads into GMP-grade exosomes for third-party non-viral drug delivery services Liège, Belgium, December 2, 2024 – EXO Biologics and its CDMO subsidiary, ExoXpert, leading innovators in ex … ation of this new unit operation to provide a seamless platform toward clinical application. The loading step is to be incorporated in ExoXpert’s cutting edge ExoPulse™ exosome manufacturing GMP platform. ExoPulse is currently being used by several partners to develop exosome-based product with a derisked path to clinical. Exosomes, as naturally occurring extracellular vesicles, are increasingly recognized for their ability to transport biologically active cargo,
EXO Biologics CEO Discusses Innovation in Developing Exosome Therapies | PharmExec --> --> News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Shorts Conferences Conference Coverage Conference Listing More Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe My Account News Academy Multimedia Conferences Publications Partner Perspectives Resources Subscribe Corporate Communications Press Releases Executive Roundtable Executive
#drugdiscovery #healthcareinnovation #mscs #extracellularvesicles #exosomes #summitspeaker | EXO Biologics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
EXO Biologics is pleased to announce 𝘁𝘄𝗼 𝗻𝗲𝘄 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀 advancing extracellular vesicle (EV) therapeutics toward clinical development. The first project is 𝗥𝗘𝗩𝗜𝗩𝗘-𝗣𝗗… | EXO Biologics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at … to contribute to bringing extracellular vesicle therapeutics closer to clinical application. 97 3 Comments Like Comment Share Copy LinkedIn Facebook X Neuro-SysMed 2mo Report this comment We're very grateful to be working with you! Looking forward to having these trials start 🧠 Like Reply 1 Reaction 2 Reactions stijn van rompay 2mo Report this comment excellent !! congrats Like Reply 1 Reaction 2 Reactions Sabine Eeckhaoudt 2mo Report this comment Interes … expression in patients with sickle cell disease and beta thalassemia recieves a grant of up to $32 million in nondilutive funding from the Japan Agency for Medical Research and Development (AMED) to support advancement through Phase 2 clinical development Emerged from a comprehensive screening campaign of approximately 140,000 compounds, followed by sophisticated molecular design using X-ray crystallographic data and the synthesis and evaluation of more than 1,000 compounds,
EXO BIOLOGICS | Mexico Business News Our Categories Entrepreneurs Tech Talent Energy Oil & Gas Mining Health Automotive Aerospace Finance & Fintech Infrastructure Sustainability Professional Services E-Commerce & Retail Agribusiness & Food Logistics Mobility Trade & Investment Policy & Economy Cybersecurity AI, Cloud & Data Chemicals Multimedia Podcast Videos Audio Articles Opinion Expert Contributor Startup Contributor Goverment Embassy Chamber of Commerce Industry Association Type Spotlight Entrepreneurs Tech Talent Energy Oil & Gas Mining Health Automotive Ae
Exoxpert, an exosome CDMO launched by Exo biologics About Us About Us Our History Leadership Team Why exosomes Services ExoPulse™ platform Buy Exosomes Process Development GMP manufacturing Facility | News Careers Contact January 31, 2024 ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes. Liege, Belgium, January 31, 2024 – EXO Biologics SA , a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, today announces the worldwide launch of ExoXpert TM , a contract developm … am? Applying for a job at ExoXpert and become a shaper of the exosome expansion Apply now Boulevard de Patience et Beaujonc 3/2 4000 Liège – Belgium +32 468-009-199 [email protected] Created by Legal Cookies Privacy Manage Cookie Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consen
EXO Biologics - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business Regulatory Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science About Us Subscribe Free Media Info Contact U
Next generation of nanomedicine therapy | EXO Biologics SA About Us Our Technology Our Pipeline News Careers Contact Us Toggle navigation Release the Power of Exosomes Extracellular Vesicles (EVs), also known as exosomes, are nanometer-sized particles naturally secreted by various cells. Exosomes have the potential to act as therapeutic messengers between cells. Therapeutic exosomes are released by cultured cells. They are considered a safer, more consistent, and more stable alternative to current cell-based therapeutic approaches. In addition, they could be highly cost-effective. Learn more O